Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • EP full-text search
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Technology insight reports
    • Data
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Technology platforms
      • Overview
      • Digital agriculture
      • Plastics in transition
      • Water innovation
      • Space innovation
      • Technologies combatting cancer
      • Firefighting technologies
      • Clean energy technologies
      • Fighting coronavirus
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
    Image
    EPO TIR study-Agriculture-web-720 x 237

    Technology insight report on digital agriculture

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • Find a professional representative
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact with us on your files
      • Online Filing & fee payment outages
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Find out how the Unitary Patent can enhance your IP strategy

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National measures relating to the Unitary Patent
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for representatives
    Image
    Law and practice scales 720x237

    Keep up with key aspects of selected BoA decisions with our monthly "Abstracts of decisions”

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • European Inventor Network
      • The 2024 event
    • Young Inventors Prize
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    From ideas to inventions: tune into our podcast for the latest in tech and IP

  • Learning

    Learning

    The European Patent Academy – the point of access to your learning

    Go to overview 

    • Overview
    • Learning activities and paths
      • Overview
      • Learning activities
      • Learning paths
    • EQE and EPAC
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Overview
      • Business and IP managers
      • EQE and EPAC Candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)
    Image
    Patent Academy catalogue

    Have a look at the extensive range of learning opportunities in the European Patent Academy training catalogue

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Sustainability at the EPO
      • Overview
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • Technologies
      • Innovation actors
      • Policy and funding
      • Tools
      • About the Observatory
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Sustainable Procurement Policy
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
      • "Long Night"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Track the latest tech trends with our Patent Index

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • New to patents
  • New to patents
    • Go back
    • Overview
    • Your business and patents
    • Why do we have patents?
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Is it patentable?
    • Are you first?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Release notes
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • EP full-text search
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Technology insight reports
    • Data
      • Go back
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
        • Boards of Appeal decisions
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Technology platforms
      • Go back
      • Overview
      • Digital agriculture
        • Go back
        • Overview
        • Plant agriculture
        • Artificial growth conditions
        • Livestock management
        • Supporting technologies
      • Plastics in transition
        • Go back
        • Overview
        • Plastics waste recovery
        • Plastics waste recycling
        • Alternative plastics
      • Innovation in water technologies
        • Go back
        • Overview
        • Clean water
        • Protection from water
      • Space innovation
        • Go back
        • Overview
        • Cosmonautics
        • Space observation
      • Technologies combatting cancer
        • Go back
        • Overview
        • Prevention and early detection
        • Diagnostics
        • Therapies
        • Wellbeing and aftercare
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
    • Helpful resources
      • Go back
      • Overview
      • First time here?
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
          • Introductory brochures
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Exchange data with us using an API
          • Go back
          • Release notes
      • Get access
        • Go back
        • Overview
        • Release notes
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact with us on your files
        • Go back
        • Release notes
      • Online Filing & fee payment outages
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Overview
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Unitary Patent Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
        • Go back
        • Travaux préparatoires to UP and UPC
      • National measures relating to the Unitary Patent 
      • International treaties
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the inventors
      • Nominations
      • European Inventor Network
        • Go back
        • Overview
        • 2026 activities
        • 2025 activities
        • 2024 activities
        • Rules and criteria
        • FAQ
      • The 2024 event
    • Young Inventors Prize
      • Go back
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • CodeFest
        • Go back
        • CodeFest 2026 on patent and IP portfolio (e)valuation
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Overview
        • CodeFest 2024 on generative AI
        • CodeFest 2023 on Green Plastics
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Future of medicine: Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • Learning activities and paths
      • Go back
      • Overview
      • Learning activities: types and formats
      • Learning paths
    • EQE and EPAC
      • Go back
      • Overview
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Compendium
          • Go back
          • Overview
          • Paper F
          • Paper A
          • Paper B
          • Paper C
          • Paper D
          • Pre-examination
        • Candidates successful in the European qualifying examination
        • Archive
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventor's handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EQE and EPAC Candidates
        • Go back
        • Overview
        • Paper F brain-teasers
        • European qualifying examination - Guide for preparation
        • EPAC
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • Core activities
          • Stories and insights
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Go back
      • Overview
      • Communiqués
        • Go back
        • 2024
        • Overview
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
        • Go back
        • Driver 1: People
        • Driver 2: Technologies
        • Driver 3: High-quality, timely products and services
        • Driver 4: Partnerships
        • Driver 5: Financial sustainability
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Sustainability at the EPO
      • Go back
      • Overview
      • Environmental
        • Go back
        • Overview
        • Inspiring environmental inventions
      • Social
        • Go back
        • Overview
        • Inspiring social inventions
      • Governance and Financial sustainability
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Dynamic Purchasing System (DPS) publications
      • Sustainable Procurement Policy
      • About eTendering
      • Invoicing
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Quality Action Plan
        • Quality dashboard
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
        • Integrated management at the EPO
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Detailed methodology
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Formalities services
          • Customer services
          • Filing services
          • Key Account Management (KAM)
          • Website
          • Archive
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • Technologies
        • Go back
        • Overview
        • Innovation against cancer
        • Assistive robotics
        • Energy enabling technologies
          • Go back
          • Overview
          • Publications
        • Energy generation technologies
        • Water technologies
        • Plastics in transition
        • Space technologies
        • Digital agriculture
      • Innovation actors
        • Go back
        • Overview
        • Startups and SMEs
          • Go back
          • Overview
          • Publications
        • Research universities and public research organisations
        • Women inventors
      • Policy and funding
        • Go back
        • Overview
        • Financing innovation programme
          • Go back
          • Overview
          • Our studies on the financing of innovation
          • EPO initiatives for patent applicants
          • Financial support for innovators in Europe
        • Patents and standards
          • Go back
          • Overview
          • Publications
          • Patent standards explorer
      • Tools
        • Go back
        • Overview
        • Deep Tech Finder
      • About the Observatory
        • Go back
        • Overview
        • Work plan
        • Collaboration with European actors
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2024
          • Go back
          • Overview
          • Executive summary
          • Driver 1 – People
          • Driver 2 – Technologies
          • Driver 3 – High-quality, timely products and services
          • Driver 4 – Partnerships
          • Driver 5 – Financial Sustainability
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Go back
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
        • Go back
        • Overview
        • Catalyst lab & Deep vision
          • Go back
          • Overview
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Previous exhibitions
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Long Night"
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Information from the Boards of Appeal
    • Procedure
    • Oral proceedings
    • About the Boards of Appeal
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions and opinions (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Annual list of cases
    • Communications
    • Annual reports
      • Go back
      • Overview
    • Publications
      • Go back
      • Abstracts of decisions
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Patent Knowledge Products and Services
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Home
  2. T 1291/22 (Oral nutritional composition/ABBOTT) 07-08-2024
Facebook X Linkedin Email

T 1291/22 (Oral nutritional composition/ABBOTT) 07-08-2024

European Case Law Identifier
ECLI:EP:BA:2024:T129122.20240807
Date of decision
07 August 2024
Case number
T 1291/22
Petition for review of
-
Application number
13817809.0
IPC class
A23L 33/00
Language of proceedings
EN
Distribution
NO DISTRIBUTION (D)

Download and more information:

Decision in EN 534.37 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

LOW VISCOSITY, HIGH CALORIC DENSITY ORAL NUTRITIONAL COMPOSITION AND RELATED METHODS

Applicant name
ABBOTT LABORATORIES
Opponent name

Nutricia Research B.V.

Fresenius Kabi Deutschland GmbH

Board
3.3.09
Headnote
-
Relevant legal provisions
European Patent Convention Art 123(2)
European Patent Convention Art 83
European Patent Convention Art 54
European Patent Convention Art 56
Rules of procedure of the Boards of Appeal Art 12(4)
Rules of procedure of the Boards of Appeal Art 12(6)
Rules of procedure of the Boards of Appeal Art 13(2)
Keywords

Amendments - allowable (yes)

Sufficiency of disclosure - (yes)

Novelty - (yes)

Inventive step - non-obvious modification

Catchword
-
Cited decisions
T 2399/10
T 0797/14
T 0842/14
Citing decisions
-

I. This decision concerns the appeals filed by opponents 1 and 2 (appellants 1 and 2) against the opposition division's interlocutory decision that the European patent as amended met the requirements of the EPC.

II. With their respective notice of opposition, opponents 1 and 2 had requested that the patent be revoked under Article 100(a) (lack of novelty and lack of inventive step), (b) and (c) EPC.

III. The documents submitted during the opposition proceedings included:

D1:|WO 2009/072885 A1 |

D5:|Mintel database: Record ID 1012294 ("Abbott Ensure TwoCal")|

D6:|WO 2010/140891 A2|

D16:|WO 2009/072886 A1|

D26:|WO 2012/008858 A1|

IV. In the decision under appeal, auxiliary request 1 (filed by letter dated 25 September 2020) was found to be allowable. This request is the main request on appeal.

V. The wording of product claims 1, 3 and 8 of the main request is relevant to this decision, and is set out below.

"1. A low viscosity, high caloric density liquid nutritional composition comprising:

a) protein in an amount of between 8 to 27 grams per 100 mL of the nutritional composition, the protein comprising (i) non-micellar milk protein isolate, non-micellar milk protein concentrate, or both, and (ii) a partially hydrolyzed caseinate; wherein the protein comprises 0-25% by weight of protein from a partially hydrolyzed caseinate; 25-50% by weight of protein selected from the group consisting of whey protein, soy protein, pea protein, potato protein and combinations thereof; and 50 to 75% by weight of non-micellar milk protein isolate, non-micellar milk protein concentrate or a combination thereof;

b) fat in an amount of between 0 and 17 grams per 100 mL of the nutritional composition; and

c) at least one emulsifier selected from the group consisting of lecithin, monoglycerides, diglycerides, polyglycerol esters, milk phospholipids, citric acid esters, datem and emulsifiers with a hydrophilic-lipophilic balance between 5 and 16, and combinations thereof;

wherein the nutritional composition has a viscosity of between 45 and 140 cps at 22 C, a caloric density of 200 to 300 kcal per 100 mL of the nutritional composition, and wherein the total combined amount of fat and protein is 8-27 grams per 100 mL of the nutritional composition."

"3. A low viscosity, high caloric density liquid nutritional composition according to claim 1, wherein the non-micellar protein is denatured through one or more of hydrolysis, heat treatment, homogenization, or reaction with soluble divalent minerals."

"8. A low viscosity, high caloric density liquid nutritional composition comprising:

a) protein in amount of between 8 to 27 grams per 100 mL of the nutritional composition;

b) fat in an amount of between 0 and 17 grams per 100 mL of the nutritional supplement;

c) an anti-foaming agent selected from the group consisting of simethicone, dimethylpolysiloxane, silicone dioxide, lecithin, milk phospholipid, and combinations thereof; and

d) a chelating agent selected from the group consisting of monovalent chelating agents, divalent chelating agents, and combinations thereof; in an amount of 0.3 weight% to 0.5 weight%;

where the protein comprises: 50-75% by weight of non-micellar milk protein isolate, non-micellar milk protein concentrate or a combination thereof; and

partially hydrolyzed caseinate in an amount of up to 50% by weight of partially hydrolyzed caseinate, or up to 25% by weight of partially hydrolyzed caseinate and 0-25% by weight of at least one protein selected from the group consisting of: micellar milk protein, non-hydrolyzed caseinate, soy, pea, whey, rice, corn, meat, fish, egg albumen, potato, canola, algal protein, mycoprotein and combinations thereof;

wherein the nutritional composition has a viscosity of between 45 and 140 cps at 22 C; wherein the composition has a caloric density of 200 to 300 kcal per 100 mL of the nutritional supplement; and wherein the total combined amount of fat and protein is 8-27 grams per 100 mL of the nutritional composition."

Claim 15 is an independent claim directed to a method for manufacturing a low viscosity, high caloric density liquid nutritional composition. The method involves the the step of adding protein comprising partially hydrolysed caseinate and non-micellar milk protein selected from the group consisting of non-micellar milk protein isolate, non-micellar milk protein concentrate, and combinations thereof. The wording of this claim is not relevant.

VI. On appeal, the patent proprietor (respondent) filed nine auxiliary requests (numbered 1 to 9). Among other things, appellant 2 filed the following document after notification of the board's communication under Article 15(1) RPBA:

D29:|K. Smith, "Dried Dairy Ingredients", Wisconsin Center for Dairy Research, 2008, 5 and 20|

VII. The following arguments were raised against the claims of the main request.

- Appellant 2 argued that claim 3 did not comply with the requirement of Article 123(2) EPC. This claim was a combination of claims 1, 3 and 4 of the application as filed. There was no basis in the application as filed for this combination.

- Appellant 1 argued that claim 8 did not comply with the requirement of Article 123(2) EPC and that claim 1 did not comply with the requirement of Article 123(3).

- Appellants 1 and 2 asserted that even when taking the description of the patent into consideration, the skilled person would not have known how to provide the non-micellar protein called for in the claims. In particular, the milk protein isolate and milk protein concentrate used in the examples of the patent were apparently in micellar form. Non-micellar milk protein isolate and non-micellar milk protein concentrate were not commercially available.

- Appellants 1 and 2 maintained that partially hydrolysed caseinate was not a mandatory feature of claims 1 and 8. The compositions claimed did not need to comprise this ingredient. It followed from this that the subject-matter of claims 1 and 8 lacked novelty over D26. In addition, appellant 1 considered these claims to lack novelty over D1.

- Appellants 1 and 2 stated that inventive step could be assessed from any of documents D1, D6, D16 or D26. Appellant 1 used D1 and D26 as starting points to outline its objections of a lack of inventive step. Appellant 2 based its objections of a lack of inventive step on either D6 or D26 as a starting point. In all cases, the conclusion was that claim 1 lacked an inventive step and the same applied to claims 8 and 15.

VIII. The respondent's arguments, where relevant to the decision, can be summarised as follows:

- Claim 3 did comply with the requirement of Article 123(2) EPC. No new combination of features was generated by the amendment in claim 1.

- Appellant 1's objections against claim 8 under Article 123(2) EPC and against claim 1 under Article 123(3) EPC had not been made prior to the appeal proceedings. They should not be admitted on appeal.

- The skilled person would have known how to produce and identify the non-micellar milk protein products called for in the claim. They simply had to break down the micellar structure of the specified protein.

- The subject-matter of claims 1 and 8 was novel. It was clear from both the wording of the claims and the patent's description that partially hydrolysed caseinate was a mandatory feature of these claims.

- The subject-matter of claims 1, 8 and 15 did involve an inventive step. The closest prior art was example 2 of D26. There were numerous distinguishing features, including the inclusion of partially hydrolysed caseinate. D1 and D6 required micellar caseinate and were not the closest prior art.

IX. Final requests

Appellants 1 and 2 requested that the decision under appeal be set aside and that the patent be revoked.

The respondent requested that the appeal be dismissed (main request) or, alternatively, that the patent be maintained in amended form based on the claims of one of auxiliary requests 1 to 4 as filed with the reply to the appellants' statements setting out the grounds of appeal, or of one of auxiliary requests 5 to 9 as filed by letter dated 7 March 2024.

1. Patent in suit

1.1 The patent is directed to nutritional compositions displaying high caloric density and low viscosity, and a method for manufacturing such compositions.

1.2 Product claims 1 and 8 of the main request are directed to compositions in which the protein comprises 50 to 75% by weight of non-micellar milk protein isolate, non-micellar milk protein concentrate or a combination thereof, and specified amounts of further protein components. Method claim 15 of the main request is directed to a method for manufacturing a low viscosity, high caloric density liquid nutritional composition. The method involves the step of adding protein comprising partially hydrolysed caseinate and non-micellar milk protein.

2. Claim interpretation

2.1 In the decision under appeal, the opposition division acknowledged that there was a discrepancy in claim 1 of the current main request; while claim 1 included the value 0% of a partially hydrolysed caseinate, this ingredient was listed as being compulsory in the nutritional composition of claim 1. However, taking the patent specification into consideration, the range "0-25%" had to be interpreted as "more than 0 to 25%".

2.2 This part of the decision was contested and the following arguments were presented.

2.2.1 The wording used in claim 1 ("comprises 0-25% by weight of protein from a partially hydrolyzed caseinate") meant that the composition of claim 1 did not necessarily comprise partially hydrolysed caseinate. The value 0% made it clear that partially hydrolysed caseinate was merely an optional ingredient of the composition of claim 1.

2.2.2 Moreover, if there were two possible interpretations, then for legal certainty the broader interpretation had to be applied, to the patent proprietor's disadvantage.

2.2.3 Furthermore, the patent's description endorsed the interpretation that partially hydrolysed caseinate was an optional ingredient. Firstly, example 2 of the patent did not (explicitly) disclose that the caseinate used was partially hydrolysed. Secondly, the patent specification referred to two passages of paragraph [0024] of the patent that confirmed this understanding and read as follows:

"When used in the disclosed liquid nutritional compositions, the partially hydrolyzed caseinate ..."

"When present in the disclosed embodiments, the partially hydrolyzed caseinate..." (emphasis added).

2.2.4 Finally, claim 8 did not require partially hydrolysed caseinate as a mandatory feature.

2.3 Interpretation of claim 1

2.3.1 Claim 1 of the application as filed and claim 1 as granted relate to a low viscosity, high caloric density liquid nutritional composition which comprises, among other things,

(i) non-micellar milk protein isolate, non-micellar

milk protein concentrate, or both, and

(ii) a partially hydrolysed caseinate

2.3.2 During the first-instance opposition proceedings, claim 1 as granted was restricted by the addition of features from dependent claim 3 as granted. Among other features, the amount of partially hydrolysed caseinate ("0-25% by weight of protein from a partially hydrolyzed caseinate") was added to claim 1.

2.3.3 Due to this amendment, claim 1 of the main request encompasses the feature:

"(i) non-micellar milk protein isolate, non-micellar milk protein concentrate, or both, and (ii) a partially hydrolyzed caseinate; wherein the protein comprises 0-25% by weight of protein from a partially hydrolyzed caseinate ..." (emphasis added by the board).

2.3.4 A straightforward reading of claim 1 imposes a specific hierarchy of the features in this claim. It is plain to see that the two ingredients (i) and (ii) of the composition of claim 1 are necessarily part of the composition.

2.3.5 After the semicolon, further features of claim 1 are specified. Among other things, the weight% distribution of the various proteins that form the composition's protein fraction is specified. In other words, the semicolon imposes a sequential reading of the claim, which involves two separate requirements. The first requirement is that partially hydrolysed caseinate is part of the composition of claim 1. This first requirement is restricted - but not eliminated - by the second requirement, namely that the amount is necessarily 0 to 25% by weight of the protein.

2.3.6 Given the specific wording and structure, claim 1 is considered to specify that the partially hydrolysed caseinate cannot be left out of the composition according to claim 1. On the contrary, it is a mandatory ingredient of claim 1. Therefore, in this claim the value 0% has to be read and understood as meaning "above 0%" (or starting from 0%, with 0% being excluded). This is the interpretation which the opposition division correctly adopted.

2.3.7 As an intermediate conclusion, it is plain to see from the wording of claim 1 alone that partially hydrolysed caseinate is a mandatory ingredient. Contrary to the appellants' view, there is only one interpretation that applies.

2.3.8 For completeness, it is noted that the patent specification supports this interpretation.

2.3.9 All three embodiments discussed in detail in the patent (paragraphs [0006] to [0008] and [0010] to [0012]) unambiguously disclose that partially hydrolysed caseinate is a mandatory ingredient. The passage to which appellant 2 referred, paragraph [0024], corroborates this. It starts as follows:

"As previously discussed, according to the first, second and third embodiments, the compositions include a partially hydrolysed caseinate".

2.3.10 Within the context of this paragraph, the features specified after the terms "[w]hen used" and "[w]hen present" (see section 2.2.3 above) are understood to define the specific partially hydrolysed caseinate that is added to the compositions of the patent. These features are not to be understood as definitions of partially hydrolysed caseinate that apply in general, i.e. outside the context of the patent and its compositions.

2.3.11 Finally, while example 2 of the patent does not explicitly disclose that the sodium caseinate used therein is partially hydrolysed, this alone cannot serve to confirm that partially hydrolysed caseinate is merely an optional ingredient of claim 1.

2.3.12 To conclude, in the context of claim 1, the value 0% has to be read and understood as meaning "above 0%".

2.4 Interpretation of claim 8

2.4.1 The appellants gave no specific reasoning for their assessment that according to claim 8 partially hydrolysed caseinate was an optional feature.

2.4.2 Claim 8 discloses that the amount of partially hydrolysed caseinate is "up to 50%" or "up to 25%", depending on the embodiment. Similar considerations to those set out with respect to claim 1 apply to the wording of claim 8. The maximum amount of partially hydrolysed caseinate ("up to 50%" or "up to 25%") in the context of claim 8 implies that the amount of this ingredient is not 0%; partially hydrolysed caseinate is a mandatory ingredient.

2.5 To conclude on claim interpretation, independent claims 1 and 8 of the main request call for partially hydrolysed caseinate as a mandatory ingredient of the low viscosity, high caloric density liquid nutritional composition. This claim interpretation will be used in the following.

3. Admittance of D29

3.1 Appellant 2 filed document D29 after notification of the board's communication under Article 15(1) RPBA. The respondent argued that this document should not be admitted into the proceedings.

3.2 Appellant 2 did not refer to any exceptional circumstances justifying the filing of this document. It had filed D29 merely to demonstrate that according to common general knowledge, to which D29 allegedly belonged, milk protein concentrate and milk protein isolate contained micellar casein and whey protein.

3.3 However, Article 13(2) RPBA makes no exception for documents considered by a party to be proof of common general knowledge. In addition, the typical composition of conventional milk protein concentrate and milk protein isolate as such is not in dispute.

3.4 Therefore, the board cannot see any reason to take this document into account in these proceedings (Article 13(2) RPBA).

4. Main request - amendments

4.1 The opposition division decided that the claims of what was then auxiliary request 1 (now the main request) complied with the requirement of Article 123(2) EPC.

4.2 Appellant 2 argued that claim 3 involved added subject-matter. Appellant 1 argued that claim 8 involved added subject-matter.

4.3 Amendment to claim 3

4.3.1 According to appellant 2, claim 3 (of the main request) was based on claim 4 of the application as filed. Claim 1 of the main request was based on a combination of claims 1 and 3 of the application as filed. It followed from this that claim 3 of the main request was a combination of claims 1, 3 and 4 of the application as filed, for which there was no basis in the application as filed.

4.3.2 It is true that claim 4 of the application as filed is not dependent on claim 3 of the application as filed. However, claim 4 of the application as filed discloses possible measures for preparing non-micellar milk protein. The only non-micellar milk proteins mentioned both in the application as filed and in the patent are non-micellar milk protein isolate and non-micellar milk protein concentrate. Therefore, claim 3 of the main request simply sets out the different ways the non-micellar protein of claim 1 of the main request can be made.

4.3.3 Paragraph [0017] of the application as filed further supports this general teaching. While further features are disclosed in this paragraph on how non-micellar proteins are prepared (e.g. homogenisation conditions), the skilled person would realise that they would not be obliged to apply all the specific embodiments or conditions taught in this paragraph. The teaching in claim 4 of the application as filed is generic.

4.3.4 Therefore, claim 3 of the main request does not encompass added subject-matter. Its combination with the subject-matter of claim 1 of the main request would be directly and unambiguously derivable for the skilled person.

4.4 Amendment to claim 8

4.4.1 Appellant 1 did not raise any objection of added subject-matter with respect to claim 8 of auxiliary request 1 before the opposition division; it did so only on appeal. The respondent argued that this was a new objection which should not be admitted into the proceedings.

4.4.2 As is clear from the minutes of the oral proceedings before the opposition division and the decision under appeal, no objection of added subject-matter was raised against claim 8, despite the fact that the claim wording had been known to the opponents for more than a year before the oral proceedings. Thus, appellant 1 could and should have presented its objection during the opposition proceedings.

4.4.3 Therefore, this objection was not admitted on appeal (Article 12(4) and (6) RPBA).

4.5 To conclude, the main request complies with the requirement of Article 123(2) EPC.

5. Main request - requirement of Article 123(3) EPC

5.1 In the decision under appeal (point 19.2.1), it is stated that the opponents had no objections under Article 123(3) EPC. However, in its statement setting out the grounds of appeal, appellant 1 did raise such an objection. The respondent argued that this new objection should not be admitted into the proceedings.

5.2 Appellant 1's objection raised on appeal represents an amendment to its appeal case. It could and should have presented its objection during the opposition proceedings.

5.3 Therefore, this objection was not admitted into the proceedings (Article 12(4) and (6) RPBA).

6. Main request - sufficiency of disclosure

6.1 The opposition division concluded that the invention set out in the claims corresponding to the current main request met the requirement of Article 83 EPC.

6.2 The appellants contested this conclusion and presented the following arguments.

6.2.1 Even when taking the description of the patent into consideration, the skilled person would not have known how to provide the non-micellar protein called for in the claims. In particular, the milk protein isolate and milk protein concentrate used in the examples of the patent were apparently in micellar form. The non-micellar protein of claim 1 was not commercially available. Decisions T 2399/10, T 797/14 and T 842/14 were cited to support these arguments.

6.2.2 In the course of the appeal proceedings and during the oral proceedings before the board, appellant 2 further refined its line of argument. It conceded that preparing non-micellar protein was trivial. However, according to common general knowledge the casein in milk protein isolate and milk protein concentrate was in micellar form. It followed from this that the skilled person would not have known how to resolve the contradiction and produce non-micellar milk protein isolate or non-micellar milk protein concentrate.

6.3 The arguments provided by the appellants have not convinced the board.

6.4 First and foremost, the skilled person knows how to destroy the micellar structure of proteins. Appellant 2 itself confirmed this during the oral proceedings before the board.

6.5 Therefore, to provide the non-micellar components of claim 1, all the skilled person has to do is break down (or denature) the micellar structure which is intrinsic to the milk protein isolate and milk protein concentrate. This way, the micellar structure originally contained in these proteins is destroyed. The resulting proteins are a non-micellar milk protein isolate and a non-micellar milk protein concentrate.

6.6 In doing this, the skilled person is not bound to instructions in the patent in suit. Instead, they can use their common general knowledge and known methods such as calcium depletion.

6.7 Against this background, it is conclusive that the patent outlines only in very generic terms what can be done to provide the non-micellar components of claim 1 ("hydrolysis, heat treatment, reaction with soluble divalent minerals, and combinations thereof" (paragraph [0018]).

6.8 As the respondent explained, micelles are identified by microscopy - and if they are not detected, then the protein examined is non-micellar. While this is not explicitly disclosed in the patent in suit, it is something that the skilled person would straightforwardly understand upon reading the patent. In view of this, the board does not consider there to be an undue burden for the skilled person to provide nutritional compositions in which the protein comprises 50 to 75% by weight of non-micellar milk protein isolate, non-micellar milk protein concentrate or a combination of the two.

6.9 On this basis, the board cannot identify any lack of sufficiency of disclosure.

6.10 For completeness, the following observations are made with respect to the additional arguments provided by the appellants.

6.10.1 Given that the skilled person can prepare the non-micellar milk protein isolate and non-micellar milk protein concentrate required by claim 1, it is not relevant whether such products can be bought. Nor is it relevant to assess whether the specific commercial milk protein products used in the examples are in a non-micellar form.

6.10.2 It follows from this that decision T 842/14, as cited by the appellants, is not relevant. This decision concerns a case in which the chemical composition of the anti-foam reagents of claim 1 was "made available to the skilled person, if at all, only by being commercially available" (Reasons, 32). In the current case, the situation is different. A specific, commercial product is not required by claim 1, and the skilled person would not be obliged to carry out the invention with a product that they cannot prepare themselves and would have to purchase.

6.10.3 For analogous reasons, T 797/14 is not relevant either. In the case underlying this decision, the preferred and unique coating composition was a product commercialised under a specific trade mark. Its composition and method of production was not public knowledge and was kept secret by the manufacturer. However, this is not the case with the non-micellar protein required by claim 1.

6.10.4 The appellants also referred to T 2399/10. However, this decision is not applicable in the current case either. T 2399/10 refers to an insufficiently disclosed dimensional parameter. The competent board considered that the method for establishing the parameter was neither disclosed in the patent nor to be found in the prior art. In contrast, the terms "non-micellar milk protein concentrate" and "non-micellar milk protein isolate" in the present case are not parameters. Rather, the terms denote a protein that is treated such that it is no longer in the form of micelles. As discussed above, such a protein can be prepared by the skilled person.

6.11 Finally, it is noted that in the decision under appeal it is stated that "calcium-depleted MPC of D26 was considered by all parties as a non-micellar MPC" (Reasons, 19.6.3). D26 is a prior-art document which was used as the closest prior art in the decision under appeal.

6.11.1 For the board, this confirms that in the field of liquid nutritional compositions, the skilled person would have known what a non-micellar milk protein concentrate ("non-micellar MPC") is. They would have been able to identify it in the prior art.

6.11.2 At this juncture it is also noted that the process for obtaining the calcium-depleted milk protein concentrate of D26 disclosed in claim 1 involves both a heat treatment and removal of calcium ions. This corresponds to the process steps for producing non-micellar protein outlined in the patent (see point 6.7 above).

6.12 To conclude, the invention is disclosed in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art (Article 83 EPC).

7. Main request - novelty

7.1 The opposition division concluded that claim 1 was novel over D1 and D26, among other documents. The appellants contested this.

7.2 The arguments of appellants 1 and 2 on a lack of novelty are based on the interpretation that partially hydrolysed caseinate is not a mandatory ingredient of the composition of claim 1. As explained in point 2 above, the board does not agree with this interpretation.

7.3 Neither D1 nor D26 discloses at least the feature of partially hydrolysed caseinate. Furthermore, the appellants' argument that the caseinate disclosed in D1 and D26 implicitly includes fragments of caseinate which the skilled person would then consider to be (trace amounts of) partially hydrolysed caseinate was not convincing. This is not what the skilled person would directly and unambiguously derive from the disclosure of D1 and D26.

7.4 On this basis, and in agreement with the opposition division's conclusion, the subject-matter of claim 1 is found to be novel over the disclosure of D1 and D26 (Article 54 EPC).

8. Main request - inventive step

8.1 The opposition division concluded that the subject-matter of claims 1 and 8 of the current main request involved an inventive step. D26 was considered to be the closest prior art. Nevertheless, the opposition division also discussed approaches starting from other documents.

8.2 The appellants stated that inventive step could be assessed starting from any of documents D1, D6, D16 or D26.

8.3 Selection of the closest prior art

8.3.1 The assessment of inventive step starting from more than one document should be the exception rather than the rule. In the current case, the opposition division identified D26 as the closest prior art. Among the documents referred to by the appellants for assessing inventive step, this is the only document that relates to a liquid nutritional composition which comprises calcium-depleted (i.e. non-micellar) milk protein concentrate (see also section 6.11 above).

8.3.2 Therefore, D26 is used as the closest prior art in the following.

8.3.3 Neither D1 nor D6 is suitable as a starting point for assessing inventive step. Both documents disclose micellar casein as a mandatory ingredient. This runs counter to the subject-matter claimed and, thus, to the purpose of the patent. In fact, in order to arrive at the claimed subject-matter starting from D1 or D6, the skilled person would have to replace large amounts (or even all) of the mandatory ingredients of micellar casein. In other words, the skilled person would have to depart from the core teaching of these two documents.

8.3.4 Appellant 2 did not set out why it considered D16 to be the closest prior art and why the claimed subject-matter was obvious starting from this document. In the absence of reasoning as to why the opposition division's conclusions were incorrect, this objection does not have to be considered.

8.3.5 To sum up, the board agrees with the opposition division that D26 is to be considered the closest prior art.

8.4 Closest prior art and distinguishing features

8.4.1 As discussed during the oral proceedings before the board, example 2 of D26 is the fat-containing, high caloric density composition from which the assessment of inventive step is to begin. The liquid nutritional composition disclosed in this example comprises calcium-depleted (i.e. non-micellar) milk protein concentrate as the only source (i.e. 100%) of protein. In view of this, the calcium-depleted protein does not provide 50 to 75% by weight of protein of non-micellar milk protein isolate or non-micellar milk protein concentrate.

8.4.2 Accordingly, claim 1 differs from example 2 of D26 at least by the following features:

- partially hydrolysed caseinate, in an amount of up to 25% by weight of protein

- non-micellar milk protein isolate or non-micellar milk protein concentrate or both, in an amount of 50 to 75% by weight of protein

- whey protein, soy protein, pea protein, potato protein or combinations thereof, in an amount of 25 to 50% by weight of protein

8.5 Technical effect and problem to be solved

8.5.1 It was in dispute between the parties whether the distinguishing features provided any specific technical effect. The patent proprietor's position was that this was the case, whereas the appellants took the view that the distinguishing features simply resulted in a further alternative to the composition of D26.

8.5.2 The opposition division regarded the objective technical problem as being to provide an alternative nutritional composition having high nutritional caloric density and a reduced viscosity. For the sake of argument, and in favour of the appellants' line of argument, the board will start from the same assumption. Considering that the subject-matter of claim 1 is found to involve an inventive step on this basis alone, it is not necessary to decide whether the distinguishing features bring about any additional technical effect.

8.5.3 At the oral proceedings before the board, appellant 2 argued that in view of the distinguishing features, partial problems had to be formulated. The aim of formulating two problems was to call out two different, sequential selections of ingredients replacing the calcium-depleted milk protein concentrate of D26. However, as the problem formulated by the board does not in itself exclude a sequential selection of ingredients, the question of whether partial problems should be formulated can remain open.

8.5.4 To conclude, the problem to be solved is to provide an alternative nutritional composition having high nutritional caloric density and a reduced viscosity.

8.6 Non-obviousness

8.6.1 In D26, the use of 100% calcium-depleted milk protein is preferred (as in example 2). However, page 8 (lines 13 to 16) of D26 discloses that "[o]ther protein that may be included in amounts up to 49% include whey proteins, preferably provided from a whey protein concentrate ...". Therefore, the only protein explicitly mentioned in D26, aside from the calcium-depleted milk protein concentrate, is whey protein. This protein may be provided as a whey protein concentrate.

8.6.2 Considering that D26 prefers the use of a single protein, namely calcium-depleted milk protein concentrate, the board cannot identify any motivation to add whey protein and then also a third protein, i.e. partially hydrolysed caseinate, while expecting the composition to still have a suitable viscosity. On this basis, the skilled person would not have been motivated to add up to 25% by weight of protein of a partially hydrolysed caseinate to the composition of D26.

8.6.3 The combination of the closest prior art with D6, for example, does not render obvious the subject-matter of claim 1 either. D6 requires high amounts of micellar casein as a mandatory ingredient and only mentions intact caseinate, whereas D26 suggests preferably using only calcium-depleted milk protein concentrate. The skilled person would not have made the adjustments the appellants suggested because this would have meant combining somewhat opposed teachings.

8.6.4 The main line of argument of appellant 2 on obviousness was that it would be obvious to replace part of the calcium-depleted milk protein concentrate by (intact) sodium caseinate. In this context, several documents were cited, including D1, D5 and D16. All these documents showed that (sodium) caseinate was commonly used in liquid enteral compositions having high energy and a high protein content. Appellant 2 further maintained that commercially available caseinates intrinsically comprised a certain amount of partially hydrolysed caseinate. It followed from this that adding caseinate led to the subject-matter of claim 1.

8.6.5 However, as already explained above, it is not convincing that starting from example 2 of D26, the skilled person would not only add whey protein but also a further, third protein. Nor is it convincing that they would replace part of the calcium-depleted milk protein concentrate with two proteins, whey protein and a further protein, namely (intact) sodium caseinate. On this basis alone, the subject-matter of claim 1 is considered to involve an inventive step.

8.6.6 In view of this, it is not necessary to decide whether adding (intact) caseinate would provide a liquid nutritional composition protein that necessarily falls under claim 1, having regard to the broad definition of partially hydrolysed caseinate of paragraph [0024] of the patent ("the term 'partially hydrolyzed caseinate' refers to a caseinate in which a portion of the protein has been hydrolyzed ... e.g., 0.5 to 10% hydrolyzed").

8.6.7 In sum, starting from the closest prior art, the subject-matter of claim 1 cannot be regarded as obvious (Article 56 EPC).

8.7 With regard to claims 8 and 15, no different, specific lines of argument were provided. It follows from this that the same conclusions as those set out with respect to claim 1 also apply to claims 8 and 15.

8.8 To conclude, the subject-matter of claims 1, 8 and 15 involves an inventive step (Article 56 EPC).

Order

For these reasons it is decided that:

The appeals are dismissed.

Footer - Service & support
  • Service & support
    • Website updates
    • Availability of online services
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility